Biosergen is seeking an industrial partner for the execution of a joint program aiming at achieving proof of concept through Phase IIa clinical studies with BSG005G for systemic fungal infections. Following successful development, the strategic partner will have an exclusive license to further develop, produce, market and sell the product. Early stage licensing may also be considered.

Biosergen’s ideal partner is a pharmaceutical or biotechnology company with a relevant product portfolio and with the capability and experience for conducting clinical and product development.

For more information please contact Peder M. Andersen MD, Chief Executive Officer.

Phone: +45 2080 2470